Endothelial progenitor cell (EPC) transplantation is a potential means of inducing neovascularization in vivo. However, the number of circulating EPC is relatively small, it may thus be necessary to enhance their proangiogenic properties ex vivo prior to injection in vivo. Fucoidan has previously been shown to potentiate in vitro tube formation by mature endothelial cells in the presence of basic fibroblast growth factor (FGF-2). We therefore examined whether fucoidan, alone or combined with FGF-2, could increase EPC proangiogenic potency in vitro. EPC exposure to 10 μg/ml fucoidan induced a proangiogenic phenotype, including cell proliferation (p < 0.01) and migration (p < 0.01); moreover, differentiation into vascular cords occurred in the presence of FGF-2 (p < 0.01). This latter effect correlated with upregulation of the cell-surface α6 integrin subunit of the laminin receptor (p < 0.05). Compared to untreated HUVEC, untreated EPC α6 expression and adhesion to laminin were enhanced two-fold. Fucoidan treatment further enhanced HUVEC but not EPC adhesion to laminin. These results show that fucoidan enhances the proangiogenic properties of EPC and suggest that ex vivo fucoidan preconditioning of EPC might lead to increased neovascularization when injected into ischemic tissues.
INTRODUCTION
Angiogenesis is a multistep process whereby new blood vessels develop from the pre-existing vasculature. It involves migration, proliferation and differentiation of mature endothelial cells, and is regulated by interactions of endothelial cells with angiogenesis-inducing factors (growth factors, cytokines, etc.) and extracellular matrix components [1] . Endothelial cells participate in the revascularization of ischemic tissues downstream of a thrombus. Endothelial progenitor cells (EPC), which originate from bone marrow, also migrate to sites of ischemia and are incorporated into neovessels [2] . EPC hold great promise as autologous cell therapy products for patients with vascular diseases associated with heart or leg ischemia [3] [4] [5] , potentially offering a safer alternative to local injection of pro-angiogenic growth factors like VEGF. Transplantation of bone marrow mononuclear cells has already been shown to improve tissue function in heart and leg ischemia [4;6-8] . However, in a murine system, only 5 to 20% of transplanted CD34 + cells were recoverable in the bone marrow, with maximal seeding occurring 1 to 3 h after infusion [9] . Furthermore, only 5% to 30% of neocapillaries originated from engrafted cells [10] [11] [12] [13] . Such a low yield implies that large blood volumes would be necessary for clinical applications. One potential way of overcoming this limitation is to enhance the angiogenic properties of EPC ex vivo. Fucoidans are high-molecular-weight sulfated polysaccharides extracted from brown seaweeds. Reduced into low-molecular-weight fractions, fucoidans have been used for in vivo studies. They exhibit the same antithrombotic activity as heparin in rabbits, but have lower anticoagulant activity and carry a lower hemorrhagic risk [14] . Besides their anticoagulant and antithrombotic activities, fucoidans can induce angiogenesis in vitro by modulating the proangiogenic properties of heparin-binding growth factors such as basic fibroblast growth factor (FGF-2). This pro-angiogenic effect is related to their molecular weight and sulfate content [15;16] . Owing to their ionic structure, fucoidans can bind a large number of proteins [17] [18] [19] . They can thereby interfere with cell-cell and cell-matrix adhesion, and promote the release of growth factors bound to the cell surface.
We have previously demonstrated that a low-molecular-weight fucoidan fraction extracted from the brown algae Ascophyllum nodosum enhances FGF-2-induced vascular tube formation by mature endothelial cells in a standard in vitro Matrigel model [20;21] . Tube formation was dependent on overexpression of the α6 subunit of the α6 β1 laminin receptor on the endothelial cell surface [20] . Unexpectedly, and contrary to results obtained with unfractionated heparin, α6 over-expression required the presence of heparan sulfate proteoglycans (FGF-2 low-affinity receptors), but not FGF-2 high-affinity receptors at the cell surface [21] .
Here we studied the effect of this fucoidan fraction on the three main steps of angiogenesis, in order to determine whether it enhances the pro-angiogenic capacity of EPC in vitro.
MATERIALS AND METHODS

Materials.
Low-molecular-weight (LMW) fucoidan was obtained by radical depolymerization of highmolecular-weight fucoidan extracted from Ascophyllum nodosum, using procedures adapted from Nardella et al. [22] . The molecular weight was determined to be 4 ± 1 kDa by highperformance steric chromatography (HPSEC) in 0.15 M NaCl, 0.005 M NaH 2 PO 4 at pH 7.0, using pullulans (Polymers Laboratories, Interchim, Paris, France) and LMW heparin fractions as standards. The chemical composition was as follows: 34% fucose, 4% galactose, 3% xylose, 3% uronic acid and 4% sulfate. FGF-2 was from Valbiotech (Paris France). Laminin and growth factor-reduced (GFR) Matrigel were from Becton-Dickinson (Le Pont de Claix, France). An R-phycoerythrin (R-PE)-conjugated mouse anti-human monoclonal antibody against CD34 and an R-PE-conjugated rat anti-human monoclonal antibody against CD31 were purchased from Immunotech (Immunotech, Marseille, France). An R-PE-conjugated rat anti-human monoclonal antibody against α 6 integrin subunits, R-PE-conjugated mouse antihuman IgG, and 7-amino-actinomycin D (7-AAD -VIA-probe TM ) were purchased from Pharmingen International (Le Pont de Claix, France). Mouse anti-human monoclonal antibodies against KDR were from Sigma (Saint Quentin Fallavier, France), Flt-1 and Tie-2 from Becton Dickinson (Le Pont-de-Claix, France) and VE-Cadherin (CD144) from Santa Cruz Biotechnology (Tebu-bio, France). RPE-conjugated goat anti-mouse F(ab') 2 and FITCconjugated phalloidin were from Beckman Coulter (Villepinte, France).
Cell isolation and EPC culture
Umbilical cord blood was diluted in an equal volume of HBSS, and mononuclear cells were isolated by density-gradient centrifugation using 1.077 g/ml Histopaque solution (Sigma Chemicals, Saint Quentin Fallavier, France) as described by Bompais et al [23] . CD34 + cells (90% purity) were selected with immunomagnetic beads and the MACS technique (Miltenyi Biotec, Paris, France). They were plated in 24-well gelatine-coated plastic culture dishes in endothelial basal medium (EBM-2; BioWhittaker, Cambrex, France) supplemented with SingleQuots endothelial growth medium and 5% FCS. After 4 days in culture, non-adherent cells were removed by thorough washing with culture medium. When an EPC colony became visible microscopically, the cells were detached with trypsin-EDTA (Eurobio, Les Ulis, France) and expanded for further analysis.
Endothelial cells from human umbilical cords (HUVEC) were isolated by enzymatic digestion as previously described [20] .
FACS Analysis
Expression of cell-surface antigens on fucoidan-treated and untreated EPC was analysed by immunofluorescence with a FACS-SORT flow cytometer (BD Biosciences). Labelling with mouse anti-human KDR, Flt-1, Tie-2 and VE-cadherin was visualised by using RPEconjugated goat anti-mouse F(ab') 2 . CD34, CD31 and α6 were used directly PE-conjugated. In each immunofluorescence experiment an isotype-matched IgG antibody was used as a control and the fluorescence intensity of stained cells was gated according to established methods. Data were analysed with CellQuest TM software (Becton Dickinson).
Outgrowth cell proliferation assay
EPC were seeded at a density of 5x10 4 per well in 24-well gelatine-coated plates and incubated overnight with EGM-2. The use of similar initial seeding densities was confirmed 16 hours after plating by measuring acid phosphatase activity as previously described [24] . All cells were then growth-arrested for 24 hours in serum-free EBM-2 2% FCS. Cells were released from growth arrest by adding basal medium, 5% FCS (referred to as basal medium), with or without various fucoidan concentrations. The cell number in each well was determined by cell titre assay 49 hours after serum stimulation, and viability was evaluated by trypan blue exclusion. Absorbance was expressed as a ratio of values obtained immediately after seeding.
Adhesion assay
Adhesion assays were performed as previously described [25] in 96-well polystyrene plates (Costar, France) precoated with murine laminin (5 µg/well) (Becton-Dickinson, France). After incubation, non-adherent cells were washed off and the number of adherent cells was determined by alkaline phosphatase assay (pNPP). Each data point was the average of 3 wells, and each experiment was performed at least 3 times. Percentage adhesion was calculated from the number of adherent cells and the total number of cells plated per well. For inhibition experiments, antibody α6 was used at 10 to 20 µg/ml, a concentration that inhibited EPC adhesion to laminin in preliminary experiments.
In vitro tube formation assay
EPC were seeded in 6-well gelatine-precoated plates at a density of 1. 5 10 5 /well. After 18 h the culture medium was replaced by medium containing the sulfated polysaccharide (10 µg/ml) supplemented with 5% FBS, with or without FGF-2 (5 ng/ml). After 36 h, EPC were detached with versene/0.01% collagenase (1/1), centrifuged at 200 g for 7 min at 4°C, washed twice with buffered Hank's, 0.5% BSA, and used for FACS analysis and tube formation assay as previously described [20] . Briefly, growth-factor-reduced Matrigel (150 μ l, 7 mg/ml, Becton Dickinson) was added to each well of refrigerated 48-well plates and allowed to solidify for at least 1 h at 37°C. Untreated EPC and EPC treated for 36 h with or without FGF-2 in the presence or absence of 10 µg/ml fucoidan were cultured for 18 h in unsupplemented medium (EBM2) with 5% FCS at 37°C in humidified air supplemented with 5% CO 2 . The cells were then fixed with 1.1% glutaraldehyde for 15 min and stained with Giemsa for 3 min. Tube formation was examined by phase-contrast microscopy. The total enclosed area delimited by the tubes and the total length of tube structures were quantified on the entire surface of each well by using Videomet software (Microvision Instruments, France).
Chemotaxis Assay
Chemotaxis was examined in 48-well modified Boyden chambers (Costar, Avon, France). Eight-micrometer pore-size polyvinylpyrrolidone-free polycarbonate Nucleopore filters (Costar, Avon, France) were coated with gelatine by immersing them overnight in a solution of 200 mg/ml gelatine in 0.1% acetic acid, and were then dried. The chamber was inserted in a 24-well culture dish containing EBM2, 5% FCS with 40 ng/ml human recombinant VEGF (positive control) or 100 ng/ml MCP-1 (negative control). Control and fucoidan-treated EPC were washed in PBS and detached with 1 mM EDTA in PBS (pH 7.4); 3 to 5x10 5 cells/ml in EBM2 supplemented with 0.1% BSA, 5% FCS were placed in the upper chamber. Migration was allowed to proceed for 6 hours at 37°C in air-5% CO 2 . Cells remaining on the upper surface of the filters were mechanically removed, and the filters were then fixed with 1.1% formaldehyde and stained with Giemsa. The number of cells that had migrated to the lower surface was determined by counting under a high-power microscope (x40 objective). All conditions used in a given experiment were tested in triplicate. A migration index was calculated as the ratio of the number of cells that migrated toward the conditioned medium to the number of cells that migrated towards serum-free culture medium.
Actin polymerisation assay
EPC seeded on multiwell slides were fixed with 4% paraformaldehyde at RT for 10 min, then washed with PBS, permeabilized with 0.2% triton and stained with FITC-conjugated phalloidin (2 mg/ml, Sigma). The cells were coverslipped with glycerol/PBS (9:1) containing Hoechst 33258 (2.5 µg/mL, Sigma) to identify cell nuclei and were evaluated by fluorescence microscopy.
Statistical Analysis
Data are expressed as means ± SEM of at least three independent experiments. Statistical analysis was based on a two-tailed t test or on ANOVA for multiple comparisons.
RESULTS
EPC exhibit higher angiogenic capacity than HUVEC
Undifferentiated progenitor cells were isolated from human umbilical cord bloods on the basis of CD34 expression. Their outgrowth was examined between 20 and 60 days and was compared to that of mature endothelial cells extracted from human umbilical veins (HUVEC). When cultured in EGM-2 medium containing specific endothelial growth factors, these human CD34 + cells formed small colonies and, after 11 days, exhibited the typical "cobblestone" morphology of endothelial cells (Fig. 1A) . The expansion of these endothelial progenitor cells (EPC) reached 10 4 -fold (n=4) after 15 days, with a doubling time 6 times shorter than that of HUVEC in the same experimental conditions (Fig. 1B) . Relative to HUVEC, EPC had a higher capacity to form capillary-like structures in the in vitro tube formation assay. In the same experimental conditions, EPC adhered very quickly, branched and formed capillary-like structures that formed enclosed areas within 18 h, whereas HUVEC only differentiated into a partially organised capillary network (Fig. 1C) .
As already reported, and despite the differences in outgrowth, HUVEC and EPC differed by their expression of the hematopoietic stem cell marker CD133. As shown in Table 1 , CD133 expression was rapidly down-regulated as EPC differentiated and, after 60 days, reached a level similar to that of HUVEC. All the following experiments were thus performed during the first 30 days of culture. EPC expressed endothelial-specific markers such as Tie-2, KDR, Flt-1, CD144 and CD31. The expression of some of these markers varied during maturation and reached levels similar to those of HUVEC (Table I) . EPC were uniformly positive for vWF, and transmission electron microscopy showed the presence of Weibel-Palade bodies [23] . The combined expression of these markers unequivocally confirmed the endothelial nature of the EPC thus obtained. 
Fucoidan enhances EPC proliferation
We first examined the effect of various fucoidan concentrations on EPC proliferation. EPC were incubated in basal medium with fucoidan concentrations ranging from 0.1 to 100 µg/ml and were counted 49 h later. Fucoidan enhanced EPC proliferation in a concentrationdependent manner, starting at 1 µg/ml, whereas it had no effect on HUVEC at concentrations below 100 µg/ml (Fig. 2) . Whatever the fucoidan concentration, EPC always proliferated significantly more strongly than HUVEC.
Fucoidan enhances FGF-2-induced vascular tube formation by EPC
EPC were incubated overnight in starvation medium then stimulated for 36 h with fucoidan in basal medium, with or without FGF-2, before seeding on Matrigel for 18 h. Without FGF-2 pretreatment (Fig. 3A) , EPC formed no tubular structures, even in the presence of 10 µg/ml fucoidan (Fig. 3B) , remaining as individual cells or small aggregates. In contrast, 18 h after seeding, FGF-2-pretreated cells were elongated and interconnected (Fig. 3C) ; the tubular network was significantly more extensive in the presence of 10 µg/ml fucoidan, inferring enhanced differentiation (1.8-fold, p<0.001) (Fig. 3D ). These latter results were similar to those obtained with HUVEC in the same conditions (p=0.112) (Fig. 3E) . The effect was fucoidan concentration-dependent and was also related to the fucoidan sulfate content, as desulfated fucoidan was less effective than the native molecule ((p<0.01; data not shown). 
Fucoidan enhances FGF-2-mediated α6 integrin over-expression by EPC
Having previously shown that increased vascular tube formation by FGF-2-treated HUVEC correlates with over-expression of the α6 integrin subunit, we suspected that α6 subunit modulation might play a role in the observed effects of FGF-2 on EPC. Tubule formation by EPC on Matrigel was totally blocked by an anti-α6 antibody but was unaffected by an irrelevant isotype-matched antibody (Fig. 4A) . The α6 integrin was more abundantly expressed on EPC than on HUVEC (190 000 vs 99 000 sites per cell, respectively; p<0.001). FGF-2 treatment led to a 1.4-fold increase (p<0.01) in α6 labelling on the EPC surface (Fig.  4B ), and to a 4.0-fold increase on the HUVEC surface (p<0.001). Fucoidan treatment of FGF-2-pretreated EPC did not lead to a significant further increase in α6 expression, whereas the same treatment of HUVEC resulted in a further 2-fold increase (p<0.001). At the same concentration (10 µg/ml), fucoidan had no effect on the expression of other endothelial markers (KDR, Flt-1, Tie-2, PECAM, CD144) (data not shown). The kinetics of the increase in α6 integrin subunit expression was examined by harvesting EPC at various times after the addition of fucoidan and FGF-2. As shown in figure 4C , the increase in expression was detected at 16 hours and continued for 72 hours. Together, these observations suggested that α6 was involved in the formation of tubular structures by fucoidan and/or FGF-2-treated EPC. 
Fucoidan pretreatment enhances HUVEC but not EPC attachment to laminin
The combination of α6 and β1 mediates cell adhesion to laminin, one of the main constituents of the basement membrane (and of Matrigel). We thus used a laminin adhesion assay to examine the functional significance of the observed increase in α6 subunit expression. Relative to HUVEC, untreated EPC showed 3-fold greater adhesion to laminin (p<0.001) (Fig. 5) . This adhesion was significantly inhibited by an anti-α6 antibody (p<0.001), but not by an isotype-matched mouse IgG. These results were consistent with the higher α6 integrin subunit expression by EPC compared to HUVEC. Fucoidan pretreatment significantly increased HUVEC adhesion to laminin (4-fold, p<0.001), but had no detectable effect on EPC adhesion. This suggested that baseline α6 subunit expression on untreated EPC was probably already sufficient for maximal adhesion to laminin. 
Fucoidan-stimulated EPC migration is associated with cytoskeleton changes.
As the integrin α6β1 can regulate the adhesion and, thus, the migration of EPC, we examined the effect of fucoidan on EPC motility and migration towards VEGF. As shown in Figure 6A , control EPC contained abundant radial stress fibres. Fucoidan treatment induced a reorganisation of the cytoskeleton, with emergence of cell protrusions characteristic of the motile and migratory phenotype (Fig. 6A) , and fucoidan-treated EPC migrated faster than untreated EPC (control, Fig. 6B ). Fucoidan-pretreated EPC were 2.5-fold more motile than control EPC (p<0.01) (Fig. 6B) . Similar results were obtained with untreated EPC when VEGF (40 ng/ml -positive control) was present in the bottom well of the chamber. Fucoidan-pretreated EPC showed filamentous actin reorganization, which generated a small frontal protrusion (Fig. 6A, arrowheads) .
Finally, fucoidan enhanced EPC chemotaxis towards VEGF (p<0.05, Fig. 6B ). 
DISCUSSION
The aim of this study was to investigate the effect of a low-molecular-weight fucoidan fraction on the angiogenic activity of endothelial progenitor cells, which are promising candidates for cellular therapy of vascular diseases. These bone marrow-derived cells are able to participate directly in collateral vessel formation and display specific functional properties relative to mature vessel-wall endothelial cells [23] .
We first confirmed that, in our experimental conditions, EPC extracted from human cord blood exhibited a stronger angiogenic capacity than mature endothelial cells (HUVEC), proliferating more strongly and producing significantly more tubular structures than HUVEC in the presence of FGF-2.
Having previously shown that fucoidan, a low-molecular-weight sulfated polysaccharide of marine origin, was able to enhance FGF-2-induced vascular tube formation by HUVEC in vitro [17, 18] , here we investigated its effect on angiogenesis induced by EPC. In the presence of FGF-2, fucoidan induces a proangiogenic phenotype in human EPC. This phenotype includes both early angiogenic events (migration, and a mild effect on proliferation) and late events (differentiation into vascular cords). Indeed, fucoidan enhanced EPC proliferation and promoted EPC motility. Fucoidan pretreatment led to EPC-actin cytoskeleton changes, with the emergence of cell protrusions. Fucoidan-treated EPC showed enhanced migration in the Boyden chamber assay, including increased chemotaxis towards VEGF. Finally, fucoidan further enhanced the formation of FGF-2-induced vascular cord-like structures in Matrigel, whereas FGF-2 alone induced only a partial network. Fucoidan did not affect α6-subunit expression by EPC cultured with FGF-2, whereas it led to α6 subunit overexpression by HUVEC in the same conditions, as previously described [20] .
An anti-α6 antibody abrogated tube formation by both EPC and HUVEC. The fucoidanmediated increase in α6 integrin subunit expression was associated with increased HUVEC adhesion to laminin. Fucoidan pretreatment significantly increased HUVEC but not EPC adhesion to laminin, and this adhesion was significantly inhibited by a anti-α6 antibody. The α6 subunit is thus involved in these effects. Differences observed between EPC and HUVEC in adhesion assays are probably due to different total expression of α6. Baseline α6 subunit integrin expression was indeed stronger on EPC than on HUVEC. Therefore, a threshold level of α6 integrin subunit expression may be required for maximal adhesion and tubular morphogenesis in Matrigel. Theoretical analyses have shown that maximum migration speed requires intermediate adhesiveness [26] . The ability of fucoidan to enhance EPC motility without increasing their adhesiveness to laminin may be thus result in an optimal enhancement of cell locomotion. In association with β1 or β4, α6 promotes cell adhesion and is thus required for endothelial cell adhesion to the underlying basement membrane, which promotes the integrity of mature vessels [27] . Our data suggest that EPC rather than HUVEC might preferentially attach to the basement membrane. This integrin profile could potentially allow circulating EPC to attach and differentiate at sites where laminin or other α6 adhesive matrices are exposed to flowing blood, after endothelial insults [28] .
Our results suggest that fucoidan interacts directly with the cell membrane and also acts indirectly via FGF-2. Fucoidan may mediate FGF-2-induced EPC differentiation by interacting with a molecule that promotes endothelial cell adhesion, migration, proliferation and differentiation and that co-operates with a growth factor receptor, transducing the intracellular signals required to induce the angiogenic phenotype. We cannot rule out the possibility that free and cell-associated fucoidan may bind FGF-2 and confer a stable, receptor-compatible conformational change upon FGF-2, which might increase the affinity of the growth factors for their receptors. Experiments underway in our laboratory indicate that FITC-fucoidan binds to the cell membrane and is internalised within 30 minutes. The putative fucoidan receptor might contain a carbohydrate-binding domain that interacts with the carbohydrate backbone of fucoidan. Candidates include E-selectin and CD44, cell adhesion molecules that are present on the endothelial cell membrane and are expressed by EPC. Fucosylation of the receptor ESL-1 (E-selectin ligand-1) is necessary for E-selectin binding to its ligand. Therefore, fucoidan, a polyfucose, can provide the appropriate structural backbone to bind selectins. This is in keeping with previous studies showing the high affinity of selectins for a high-molecular-weight commercial fucoidan preparation [29] [30] [31] . However, a recent study showed that a commercial fucoidan was also able to bind to non selectin receptors such as integrin α M β2 on myeloid cells [32] . Integrins can transduce extracellular signals analogous to signal transduction by growth factor receptors [33] . Future studies in our laboratory will address this question.
In summary, by endowing EPC with the capacity to migrate faster and to form an extensive tubular network, fucoidan pretreatment could be used for ex vivo expansion of EPC-based cell therapy products. This could enhance EPC-mediated vasculogenesis and homing, thereby improving treatment efficacy.
